Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies

@article{ZanottiFregonara2013SuggestedPT,
  title={Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies},
  author={Paolo Zanotti-Fregonara and Adriaan A. Lammertsma and Robert B. Innis},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2013},
  volume={40},
  pages={1781-1783}
}
Dear Sir, Labeling new radioligands with F has several advantages because of the longer half-life of F (about 110 min) compared to that of C (about 20 min). This longer half-life makes an on-site cyclotron unnecessary. Furthermore, measurements of radioactivity concentrations in the brain with PET as well as in plasma with liquid chromatography are more robust. However, a longer half-life also yields a higher radiation burden. Before testing a new radioligand in humans, dosimetry studies are… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

ICRP Publication 106 : radiation dose to patients from radiopharmaceuticals — addendum 3 to ICRP publication 53

  • HM Deloar, T Fujiwara, M Shidahara, T Nakamura, H Watabe, Y Narita
  • 2008

Similar Papers

Loading similar papers…